Quarterly report pursuant to Section 13 or 15(d)

Note 15 - Segments - Segment Information (Details)

v3.19.1
Note 15 - Segments - Segment Information (Details) - USD ($)
 3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Dec. 31, 2018
Revenue from contract with customer $ 14,000 $ 16,000  
Sublease revenue 94,408  
Grant and other revenue 38,474 275,650  
Revenue 136,032 276,445  
Cost of revenue 6,126 318  
Research and development expenses 740,583 998,956  
Selling, general and administrative expenses, excluding depreciation and amortization [1] 1,786,145 1,738,385  
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 36,779 37,987  
Loss from operations [3] (2,433,601) (2,499,201)  
Other income [4] 8,713 (4,238,761)  
Provision for income taxes (876)  
Net loss from continuing operations (2,425,764)    
Loss from discontinued operations, net of tax (3,297)    
Net income (loss) (2,429,061) (6,737,962)  
Total assets, net of depreciation and amortization 4,959,760   $ 7,021,527
Capital expenditures  
UNITED STATES      
Total assets, net of depreciation and amortization 4,948,736 18,294,844  
Non-US [Member]      
Total assets, net of depreciation and amortization 11,024 27,383  
Royalty [Member]      
Revenue from contract with customer 3,150 795  
Diagnostics Segment [Member]      
Sublease revenue    
Grant and other revenue 35,991 232,436  
Revenue 39,141 233,231  
Cost of revenue 6,126 318  
Research and development expenses 740,583 785,011  
Selling, general and administrative expenses, excluding depreciation and amortization [1]  
Depreciation, Depletion and Amortization, Nonproduction, Total [2]  
Loss from operations [3] (707,568) (552,098)  
Other income [4]  
Provision for income taxes (256)    
Net loss from continuing operations (707,824)    
Loss from discontinued operations, net of tax (3,297)    
Net income (loss) (711,121) (552,098)  
Capital expenditures  
Diagnostics Segment [Member] | UNITED STATES      
Total assets, net of depreciation and amortization 55,213 13,077,979  
Diagnostics Segment [Member] | Non-US [Member]      
Total assets, net of depreciation and amortization 10,422 26,055  
Diagnostics Segment [Member] | Royalty [Member]      
Revenue from contract with customer 3,150 795  
Therapeutics Segment [Member]      
Sublease revenue    
Grant and other revenue 2,483 43,214  
Revenue 2,483 43,214  
Cost of revenue  
Research and development expenses 213,945  
Selling, general and administrative expenses, excluding depreciation and amortization [1] 11,714 8,607  
Depreciation, Depletion and Amortization, Nonproduction, Total [2]  
Loss from operations [3] (9,231) (179,338)  
Other income [4]  
Provision for income taxes (3)    
Net loss from continuing operations (9,234)    
Loss from discontinued operations, net of tax    
Net income (loss) (9,234) (179,338)  
Capital expenditures  
Therapeutics Segment [Member] | UNITED STATES      
Total assets, net of depreciation and amortization 2,411 27,228  
Therapeutics Segment [Member] | Non-US [Member]      
Total assets, net of depreciation and amortization  
Therapeutics Segment [Member] | Royalty [Member]      
Revenue from contract with customer  
Corporate Segment [Member]      
Sublease revenue 94,408    
Grant and other revenue  
Revenue 94,408  
Cost of revenue  
Research and development expenses  
Selling, general and administrative expenses, excluding depreciation and amortization [1] 1,774,431 1,729,778  
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 36,779 37,987  
Loss from operations [3] (1,716,802) (1,767,765)  
Other income [4] 8,713 (4,238,761)  
Provision for income taxes (617)    
Net loss from continuing operations (1,708,706)    
Loss from discontinued operations, net of tax    
Net income (loss) (1,708,706) (6,006,526)  
Capital expenditures  
Corporate Segment [Member] | UNITED STATES      
Total assets, net of depreciation and amortization 4,891,112 5,189,637  
Corporate Segment [Member] | Non-US [Member]      
Total assets, net of depreciation and amortization 602 1,328  
Corporate Segment [Member] | Royalty [Member]      
Revenue from contract with customer  
[1] General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments, other than those expenses directly incurred by MT.
[2] Depreciation and amortization is reflected in selling, general and administrative expenses ($36,779 and $37,987 for the three-month periods ended March 31, 2019 and 2018, respectively).
[3] Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments, other than those expenses directly incurred by MT.
[4] Amounts consist primarily of losses on debt extinguishment, interest income and interest expense, which are not currently allocated to our individual reportable segments.